Vitiligo Disease

DESCRIPTION
An acquired, slowly progressive depigmenting condition in small or large areas of the skin due to the disappearance of previously active melanocytes
  • Type A is non-dermatomal and widespread. It represents 75% of cases
  • Type B is dermatomal or segmental. It represents the remaining 25% of cases
  • System(s) affected: Skin/Exocrine
  • Genetics: Autosomal dominant with variable expression and incomplete penetrance. Positive family history in 30% of cases.
  • Incidence/Prevalence in USA: 1000-2000/100,000
  • Predominant age: All ages: 50% begin between ages 10 and 30
  • Predominant sex: Male = Female
SIGNS AND SYMPTOMS
  • Loss of pigment
  • Locally increased sunburning
  • Predilection for acral areas and around orifices such as eyes, mouth, anus
  • Pruritus (10%)
  • Premature graying (35%)
  • Koebner's phenomenon (aggravation by trauma)
CAUSES
Etiology is unclear, but is thought to be an autoimmune reaction to preexisting melanocytes
RISK FACTORS
  • Positive family history
  • Autoimmune disorders including hemolytic anemia and adrenal insufficiency
LABORATORY

Routine blood and urine studies are usually normal in the absence of associated diseases in adults. In children screen for autoimmune diseases with TSH, CBC, and fasting glucose.

Drugs that may alter lab results: N/A
Disorders that may alter lab results: N/A

PATHOLOGICAL FINDINGS
Complete absence of melanocytes in skin biopsy. At the margins one may see a few lymphocytes and large melanocytes with abnormal melanosomes.
SPECIAL TESTS
N/A
IMAGING

N/A

DIAGNOSTIC PROCEDURES
  • Examination under Wood's light accentuates the hypopigmented areas, especially in light-skinned individuals
  • Skin scraping and a potassium hydroxide (KOH) preparation can be examined microscopically to rule out tinea versicolor
APPROPRIATE HEALTH CARE

Outpatient except in rare cases of surgical skin-grafting or transplantation

GENERAL MEASURES
  • Sun exposure can accentuate the difference between normal and abnormal skin, so for cosmetic reasons patients may wish to avoid this
  • Skin dyes and cosmetics may be used as cover-ups
SURGICAL MEASURES

N/A

ACTIVITY

Full activity

DIET

No special diet

PATIENT EDUCATION
  • Reassure patient that in absence of associated autoimmune illness the problem is purely cosmetic. Successful cosmetic cover-up is usually quite simple. Some areas offer vitiligo support groups.
  • Information available through National Vitiligo Foundation, P.O. Box 6337, Tyler TX 75711; (903)531-0074
PREVENTION/AVOIDANCE

While undergoing all therapies, avoid excessive sun exposure

POSSIBLE COMPLICATIONS
  • Phototoxic reactions ranging from mild to severe with PUVA
  • Skin atrophy and telangiectasias with topical steroids
  • Contact dermatitis can occur with use of depigmenting agents and cosmetic covers
EXPECTED COURSE AND PROGNOSIS
  • Only 5% spontaneously repigment
  • Best results are with PUVA therapy where 70% have repigmentation of head and neck area, less in other body areas. Lower percentages respond to topical therapy
  • There is no response in at least 20% of cases, especially long-standing cases
  • Once repigmentation occurs it usually persists
ASSOCIATED CONDITIONS
  • Addison's disease
  • Alopecia areata
  • Chronic mucocutaneous candidiasis
  • Diabetes mellitus
  • Hypoparathyroidism
  • Melanoma
  • Pernicious anemia
  • Polyglandular autoimmune syndrome
  • Thyroid disorders (hyper- and hypothyroidism) - 30% of patients with vitiligo
  • Uveitis
  • Halo nevi
AGE-RELATED FACTORS

Pediatric: Childhood vitiligo is a distinct subset of vitiligo. Higher incidence of Type B (segmental) vitiligo. Also higher incidence of autoimmune and endocrine disease. Response is poor to topical PUVA therapy, but can be tried. Topical steroids may be prescribed, e.g., ´desonide´ 0.05% cream qDay for 4 months
Geriatric: NA
Others: NA

PREGNANCY

Treatment with topical or oral psoralens is contraindicated

OTHER NOTES

If PUVA therapy considered, dermatologic consultation should be considered

ABBREVIATIONS

CBC = complete blood count

Clinical Investigations

ROLE OF HOMOEOPATHY

Copyright © 2025 Selkey. All Rights Reserved.